The other big looming bad that we’ve perhaps not given due attention to is the impact of Brexit on everyday life.
Packages have gone missing, customs forms are causing headaches, and across Europe, people are starting to face charges they never expected to pay, and refusing the charge.
But before the rejected goods – as well as the 30% of all online sales which are returned for other reasons – can come back to the seller, they must first pass through another set of obstacles to get back into the UK, each with a list of associated charges.
At the other side of things, Brits in Europe (and Europeans in the UK) are trying to work out just where they fit. In Belgium, the framework for the much talked about new status seems to exist – however, phonecalls to actually sort it out have been raising problems.
How has your experience been? Faced a surcharge from an online store? Hit an administrative burden? We haven’t even started to talk travel.
Brussels most recent moves towards low-speed zones and more pedestrian zones have drawn criticism from pro vehicle groups, as the city struggles between a depiction as ‘anti-car’ and ‘pro-pedestrian.’ Read More.
Reopening hairdressers and other contact professions in Belgium on 13 February is “totally unfeasible,” according to virologist Marc Van Ranst.
The 13 February date, that was mentioned by Prime Minister Alexander De Croo following the Consultative Committee on Friday, for the restart of contact professions on the condition that the figures evolve favourably, worries the virologist. Read More.
While continuous surveillance of Belgium’s borders is impossible, the police will endeavour to enforce the ban on non-essential travel issued on Friday by the Consultative Committee, according to Interior Minister Annelies Verlinden. Read more.
An anti-inflammatory drug used normally on gout patients has proved effective in treating complications linked to Covid-19, the Institut de cardiologie de Montréal (ICM – Montreal Institute of Cardiology) announced on Saturday on its website. Read More.